VCXB vs. CLLS, GNFT, BCAB, XFOR, CRDF, SCLX, ELEV, CGEN, OPT, and CRDL
Should you be buying 10X Capital Venture Acquisition Corp. III stock or one of its competitors? The main competitors of 10X Capital Venture Acquisition Corp. III include Cellectis (CLLS), Genfit (GNFT), BioAtla (BCAB), X4 Pharmaceuticals (XFOR), Cardiff Oncology (CRDF), Scilex (SCLX), Elevation Oncology (ELEV), Compugen (CGEN), Opthea (OPT), and Cardiol Therapeutics (CRDL). These companies are all part of the "biological products, except diagnostic" industry.
Cellectis (NASDAQ:CLLS) and 10X Capital Venture Acquisition Corp. III (NYSE:VCXB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
In the previous week, Cellectis had 3 more articles in the media than 10X Capital Venture Acquisition Corp. III. MarketBeat recorded 3 mentions for Cellectis and 0 mentions for 10X Capital Venture Acquisition Corp. III. 10X Capital Venture Acquisition Corp. III's average media sentiment score of 1.08 beat Cellectis' score of 0.00 indicating that Cellectis is being referred to more favorably in the media.
Cellectis received 404 more outperform votes than 10X Capital Venture Acquisition Corp. III when rated by MarketBeat users.
10X Capital Venture Acquisition Corp. III has a net margin of 0.00% compared to 10X Capital Venture Acquisition Corp. III's net margin of -1,087.66%. Cellectis' return on equity of 0.00% beat 10X Capital Venture Acquisition Corp. III's return on equity.
Cellectis presently has a consensus target price of $8.50, indicating a potential upside of 181.46%. Given 10X Capital Venture Acquisition Corp. III's higher possible upside, research analysts plainly believe Cellectis is more favorable than 10X Capital Venture Acquisition Corp. III.
63.9% of Cellectis shares are owned by institutional investors. Comparatively, 13.3% of 10X Capital Venture Acquisition Corp. III shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 71.5% of 10X Capital Venture Acquisition Corp. III shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
10X Capital Venture Acquisition Corp. III has lower revenue, but higher earnings than Cellectis.
Cellectis has a beta of 3.08, meaning that its stock price is 208% more volatile than the S&P 500. Comparatively, 10X Capital Venture Acquisition Corp. III has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500.
Summary
Cellectis beats 10X Capital Venture Acquisition Corp. III on 8 of the 13 factors compared between the two stocks.
Get 10X Capital Venture Acquisition Corp. III News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCXB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
10X Capital Venture Acquisition Corp. III Competitors List
Related Companies and Tools
